StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Acadia Pharma (ACAD) Stock Soars on Positive Rett Syndrome Results, Analysts Still Not Convinced
December 7, 2021 8:17 AM
Shares of Acadia Pharma (NASDAQ: ACAD) are up nearly 20% in pre-open Tuesday after the company reported positive top-line results ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Goldman Sachs
December 7, 2021 6:39 AM
Acadia’s (ACAD) Rett Syndrome Data Adequate for Approval, Stock Gains Are Justified - Analyst
December 7, 2021 6:14 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Citi
December 7, 2021 5:22 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $23 at Oppenheimer
December 7, 2021 5:15 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $24 at Morgan Stanley
December 7, 2021 2:39 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $39 at JMP Securities
December 7, 2021 2:02 AM
